69O Stock Overview
A clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aelis Farma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.78 |
| 52 Week High | €13.45 |
| 52 Week Low | €2.76 |
| Beta | 0.21 |
| 11 Month Change | -20.57% |
| 3 Month Change | -75.40% |
| 1 Year Change | -79.02% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| 69O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -0.7% | -0.02% |
| 1Y | -79.0% | -17.2% | 8.2% |
Return vs Industry: 69O underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 69O underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 69O volatility | |
|---|---|
| 69O Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 69O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 69O's weekly volatility has increased from 9% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 26 | Pier Piazza | www.aelisfarma.com |
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Aelis Farma SA Fundamentals Summary
| 69O fundamental statistics | |
|---|---|
| Market cap | €39.22m |
| Earnings (TTM) | -€7.03m |
| Revenue (TTM) | €10.78m |
3.6x
P/S Ratio-5.6x
P/E RatioIs 69O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 69O income statement (TTM) | |
|---|---|
| Revenue | €10.78m |
| Cost of Revenue | €0 |
| Gross Profit | €10.78m |
| Other Expenses | €17.81m |
| Earnings | -€7.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.00% |
| Net Profit Margin | -65.19% |
| Debt/Equity Ratio | 39.4% |
How did 69O perform over the long term?
See historical performance and comparison